KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Biotechnology

Healthcare
$27.00 +0.00%

+$0.00 today

Market cap
$1.44B
Beta
-0.11
P/E (TTM)
-9.9
EPS (TTM)
-$2.74
52W Low $9.83High $27.00

Volume 4.26M

Average 3.47M

KALV Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

KalVista Pharmaceuticals, Inc.NASDAQ: KALV

Gross Margin · Q4 FY2026 · quarter ended Dec 2025

Gross margin at 91.6%

Gross margin was 91.6% in Q4 FY2026. On a trailing-twelve-month basis it was 92.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
91.6%+0.6 pp QoQ
Last fiscal yearDec 2025
91.7%— YoY
LTMDec 2025
92.0%— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2026
91.7%
Year-over-year change
—

Gross Margin vs competitors

How KALV compares with its peers on the latest reported figures

  • KALV's LTM Dec 2025 gross margin of 92.0% is the 3rd highest of the 9 companies compared; the peer median is 65.3%.
KALV Competitors Peer median
Gross Margin for KALV and competitors
Company Period LTM level YoY 3-year change
GOSSGossamer Bio, Inc.LTM Mar 202699.6% -0.4 pp—
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202693.4% +3.7 pp-5.2 pp
KALVKalVista Pharmaceuticals, Inc.LTM Dec 202592.0% ——
ADCTADC Therapeutics S.A.LTM Mar 202690.7% -2.0 pp-7.9 pp
VSTMVerastem, Inc.LTM Mar 202683.7% -16.3 pp-17.1 pp
PRTAProthena Corporation plcLTM Mar 202646.8% -53.2 pp-38.2 pp
BCYCBicycle Therapeutics plcLTM Mar 2026-11.9% +506.2 pp+0.0 pp
OMEROmeros CorporationLTM Mar 2026-12.4% ——
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-12.4% +490439.7 pp+2555.9 pp
OLMAOlema Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding KALV) 65.3%-0.4 pp-6.5 pp

Competitors are the stored peer set for KALV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
FY2026
Dec 2025
Revenue000073.62M
Cost of Revenue0086.17M06.08M
Gross Profit00(86.17M)067.54M
Gross Margin————91.7%
Research & Development70.17M80.28M86.17M71.71M55.64M
Selling, General & Admin26.45M30.6M54.28M116.29M183.74M
Operating Expenses96.61M110.87M54.28M188M239.38M
Depreciation & Amortization564K718K816K941K1.45M
EBITDA(80.75M)(94.37M)(134.28M)(173.33M)(150.62M)
EBITDA Margin————-204.6%
Operating Income(96.61M)(110.87M)(140.45M)(188M)(171.84M)
Operating Margin————-233.4%
Interest Income1.09M2.23M3.9M6.44M8.68M
Interest Expense0005.79M19.34M
Other Income / Expenses14.27M17.96M5.35M7.94M420K
Income Before Tax(82.34M)(92.91M)(135.1M)(180.05M)(171.42M)
Pre-Tax Margin————-232.9%
Income Tax Expense00(8.45M)3.39M(7.13M)
Net Income(82.34M)(92.91M)(126.64M)(183.44M)(164.29M)
Net Margin————-223.2%
EPS (Basic)(3.36)(3.33)(3.44)(3.69)(3.23)
EPS (Diluted)(3.36)(3.33)(3.44)(3.69)(3.23)
Weighted Avg Shares24.47M27.89M36.79M49.65M50.9M
Weighted Avg Shares (Diluted)24.47M27.89M36.79M49.65M50.9M

KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

Intrinsic Alpha fair value

Locked

Current Price

$27.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.